Company Description
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States.
The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation and delivers a binary prediction on the wounds capacity to heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed decision regarding the treatment of the patient’s wounds.
Its system also develops AI-Burn software and MSI imaging technology, which consists of proprietary multi-spectral optics and sensors that capture injured tissue images.
Spectral AI, Inc. is headquartered in Dallas, Texas.
| Country | United States |
| Founded | 2013 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Vincent Capone |
Contact Details
Address: 2515 McKinney Avenue, Suite 1000 Dallas, Texas 75201 United States | |
| Phone | 972 499 4934 |
| Website | spectral-ai.com |
Stock Details
| Ticker Symbol | MDAI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001833498 |
| CUSIP Number | 84757T105 |
| ISIN Number | US84757T1051 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Wensheng Fan | Co-Founder, Chief Innovation Strategist and Senior Advisor to the Chief Executive Officer |
| Vincent Stanley Capone Esq. | Chief Executive Officer and Corporate Secretary |
| Dr. John Michael DiMaio M.D. | Founder and Chairman |
| Stanley Micek | Chief Operating Officer |
| Allison Kumar | Head of Regulatory Affairs and Clinical Trials |
| Louis Percoco | General Manager |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2026 | 8-K | Current Report |
| Apr 16, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 16, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 8, 2026 | 8-K | Current Report |
| Apr 6, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 25, 2026 | 8-K | Current Report |
| Mar 25, 2026 | 10-K | Annual Report |
| Mar 20, 2026 | 8-K | Current Report |
| Mar 18, 2026 | SCHEDULE 13D/A | Filing |
| Feb 11, 2026 | SCHEDULE 13G | Filing |